Dublin, Dec. 17, 2018 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market by Type and Application - Global Opportunity Analysis and Industry Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
According to the report, the global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is expected to reach $65,427 million by 2025, growing at a CAGR of 25.6% from 2018 to 2025.
Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in incidence of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in adoption of immune checkpoint inhibitor drugs.
In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.
Based on type, the global immune checkpoint inhibitors market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. However, PD-L1 inhibitor segment is projected to exhibit the fastest growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D for combination studies of PD-L1 inhibitors for newer indications.
By application, the market is classified into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due to increase in use of immune check point inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due to increase in incidence of bladder cancer.
Based on type, the PD-L1 inhibitor segment is expected to experience rapid growth, registering a CAGR of 28.6% from 2018 to 2025.
Depending on application, the lung cancer segment held nearly half of the global market share in 2017, and is expected to remain dominant throughout the forecast period.
Region wise, Asia-Pacific is estimated to grow at a CAGR of 27.7% during the forecast period.
North America accounted for more than one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This is attributed to increase in demand for immune checkpoint inhibitors, high prevalence of cancer, rise in number of trained medical professionals, and supportive reimbursement policies in the healthcare system.
However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to upsurge in prevalence of cancer coupled with increase in adoption of immune checkpoint inhibitors.
Key Players
List of Other Players in the Value Chain
Topics Covered
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
3.3.1.4. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Higher cost of immune checkpoint inhibitors
3.3.3. Opportunities
3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in the emerging markets
3.3.4. Impact analyses
3.4. Clinical trials
3.5. Pipeline analyses
CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE
4.1. Overview
4.2. CTLA-4 inhibitor
4.3. PD-1 inhibitor
4.4. PD-L1 inhibitor
CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION
5.1. Overview
5.2. Lung cancer
5.3. Bladder cancer
5.4. Melanoma
5.5. Hodgkin lymphoma
5.6. Others
CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION
6.1. Overview
6.2. North America
6.3. Europe
6.4. Asia-Pacific
6.5. LAMEA
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.2. Bristol-Myers Squibb Company
7.3. Eli Lilly and Company (ARMO BioSciences)
7.4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
7.5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
7.6. Immutep Limited
7.7. Merck & Co., Inc.
7.8. Merck KGaA (EMD Serono, Inc.)
7.9. Novartis AG
7.10. Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/research/sw7ccn/the_65_bn?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs